Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

EdiGene Adds $11 Million to Pre-B Round for Novel Drugs Based on Gene Editing

publication date: Sep 16, 2019

Beijing's EdiGene raised $11 million in a Series pre-B2 financing to develop novel therapeutics based on gene editing following earlier $15 million and $10 million pre-B financings. In addition, EdiGene announced a research collaboration with a clinical stage biopharma that is developing novel off-the-shelf T-cell therapies for cancer. No further details of the partnership were disclosed. Participants in the latest funding are Series A lead investor IDG Capital and Series pre-B lead investor Lilly Asia Ventures. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital